Combination therapy for liver cancer with portal hypertension
Part of Digestive system clinical trials.
This study tests a combination therapy for liver cancer that cannot be surgically removed. It includes a procedure called TACE (which blocks the tumor's blood supply), along with targeted therapy (lenvatinib), immunotherapy (tislelizumab), and a blood pressure medicine (carvedilol) that may also help the liver. The goal is to see if this combination is safe and effective for people who also have high blood pressure in the liver's blood vessels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with liver cancer that has not been treated before.
- You have at least one tumor that can be seen on a CT or MRI scan (at least 1 cm across).
- Your liver function is relatively good (Child-Pugh score 7 or less, meaning no fluid in the belly or confusion).
- You have evidence of increased blood pressure in the liver's blood vessels (portal hypertension) — for example, enlarged veins in the stomach or esophagus, or high liver stiffness on a special test.
- You are generally able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways to deliver chemotherapy into the liver—TACE (a targeted injection that blocks blood flow) and HAIC (a continuous infusion through a small tube)—along with an immunotherapy drug (PD-1 inhibitor) and a targeted therapy pill (lenvatinib). It's for people with liver cancer that cannot be removed by surgery.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
This trial tests a combination of blood-vessel–targeting medicine and immunotherapy after a liver-directed treatment called TACE for advanced hepatocellular carcinoma (HCC). It aims to control tumor growth when surgery or ablation isn’t suitable, and to see if this “conversion therapy” helps patients do better than standard pathways.
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.